miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients.

It is clear that several prostate cancers remain indolent whereas others develop into advanced forms. There is a need to improve patient management by identifying biomarkers for personalized treatment. We demonstrated that miR-15/miR-16 loss, miR-21 upregulation, and deregulation of their target genes represent a promising predictive signature of poor patient prognosis.